The faces of Dynamic42: Thomas Sommermann
Lately Thomas Sommermann joined Dynamic42. Thomas is an experienced scientist in the field of immunology and shares our vision regarding the enormous potential of the organ-on-chip technology. Therefore, we are very happy to have him support our research team!
From Nuremberg to Jena via Cambridge and Berlin
Thomas joins us from the Hans Knöll Institute (HKI), where he was a senior postdoc and head of the cell sorting facility at the Infection Immunology department of Professor C. Zielinski. In his role he performed spectral, high-dimensional FACS (Fluorescence Activated Cell Sorter) analyses and sorting of immune cells especially human T cells.
Thomas began his carrier at the Friedrich-Alexander University of Nuremberg-Erlangen, where he studied biology with a focus on molecular cell biology in the field of colorectal cancer.
After successfully completing his diploma, he was offered a PhD-student fellowship at Harvard University in Cambridge, USA. In his PhD work Thomas addressed cell signaling and cell metabolism of lymphomas associated with Epstein-Barr virus.
Thomas’ then joined the department of Immune Regulation and Cancer at the Max Delbrück Center in Berlin. There he continued his research on lymphomas and the Epstein-Barr virus using transgenic mouse models.
Diversification of immune cell types: Thomas’ goals at Dynamic42
Having worked extensively with mouse models, Thomas is sure that there are limitations to translating findings from animal research into the human system, creating a fundamental need to develop novel complementary and alternative methods to animal testing.
``I strongly believe that organ chip technology has the potential to provide more reliable preclinical data than current animal-based experiments.``
Thomas will now promote the efforts of Dynamic42 to further integrate various immune cell populations into organ-chips. Immunocompetent organ models better mimic real body physiology and will allow D42 to address the effects of treatment approaches on immune cells within the target tissue.
More interesting articles:
Blog, Disease-Modeling, Gut-on-Chip, Infection-Modeling
When butyrate drops, the gut loses more than a metabolite – it loses resilience
In this new study by Manuel Allwang, Maximilian Wipplinger, and Parastoo Akbarimoghaddam and colleagues, published in Small, the authors show why that loss may be especially important when inflamed tissue is challenged by the opportunistic fungus Candida albicans.
Read MoreBlog, Drug Development, Liver-on-Chip
Evaluation of a liver-chip model for clearance prediction
In this new publication led by scientists at Novartis and the University of Tübingen, the authors take a deep, engineering level look at the performance of a microphysiological liver on chip model for predicting human hepatic clearance, a central parameter in preclinical drug development.
Read MoreBlog, Gut-on-Chip, Infection-Modeling
Modeling Clostridioides difficile toxin pathogenesis and antiserum protection
In this new study from Jena University Hospital and the Paul-Ehrlich-Institute, the authors show that how we model Clostridioides difficile toxin exposure fundamentally shapes our ability to understand epithelial damage, immune activation, and therapeutic protection.
Read More